The Prognostic Value of One-Step Nucleic Acid
Amplification (OSNA) and Immunohistochemistry (IHC)
in Ex Vivo Sentinel Lymph Nodes in Stage I & II Colonic
Cancer Patients - A Multicenter Cohort Study
Volume 3 - Issue 4
RLA van der Linden1*, JC van der Linden2, FJ Vogelaar3, DJ Lips1, CJH van de Velde4 and K Bosscha1
- 1Department of Surgery, Jeroen Bosch Hospital, Netherlands
- 2Department of Pathology, Jeroen Bosch Hospital, Netherlands
- 3Department of Surgery, Vie Curi Medical Center, Netherlands
- 4Department of Surgery, Leiden University Medical Center, Netherlands
Received:April 06, 2020 Published: April 16, 2020
Corresponding author: RLA van der Linden, Department of Surgery, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands
DOI: 10.32474/OAJOM.2020.03.000169
Fulltext
PDF
To view the Full Article Peer-reviewed Article PDF
Abstract
Introduction: Sentinel lymph node (SLN) mapping with multilevel-sectioning and immunohistochemistry (IHC) or One-
Step Nucleic Acid Amplification (OSNA) are considered promising techniques to improve LN staging in colon cancer. This study
investigates the prognostic significance of OSNA- and IHC-analysis of ex vivo SNLs of stage I&II colon cancer patients.
Methods: 86 stage I&II colon cancer patients were identified from two previously conducted cohort studies. All SLNs were
examined with Hematoxylin & Eosin-staining (H&E), multilevel-sectioning with IHC and OSNA analysis. Kaplan-Meier and coxregression
analysis were performed to determine the prognostic significance.
Results: Mean disease-free survival (DFS) for OSNA-positive vs OSNA-negative patients was 62.5 vs 62.0 months (p=0.886)
and for IHC-positive vs IHC-negative patients 58.1 vs 62.9 months (p=0.519). Cox-regression analysis showed that positive OSNAstatus
was not prognostic for DFS (hazard ratio (HR)=0.89, p=0.886). Additionally, also positive IHC-status showed no significant
difference for DFS (HR 1.47, p=0.522).
Conclusions: Additional OSNA or IHC-analysis of ex vivo SLNs does not provide a more accurate prognostic value in this small
group of stage I&II colon cancer patients compared with conventional H&E. A bigger study is needed to set these results in a broader
perspective. Further research is required to identify other clinically relevant upstaging techniques and prognostic factors to tailor
the treatment plans of these patients.
Abstract|
Introduction|
Material and Methods|
Results|
Discussion|
Acknowledgement|
Statement of Ethics and Funding Sources|
References|